Regeneron Pharmaceuticals...

NASDAQ: REGN · Real-Time Price · USD
574.30
8.33 (1.47%)
At close: Aug 15, 2025, 1:10 PM

Regeneron Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
14.2B 13.12B 12.17B 16.07B
Cost of Revenue
2.45B 2.24B 1.71B 2.72B
Gross Profit
11.75B 10.87B 10.47B 13.35B
Operating Income
4.17B 4.35B 5.39B 8.95B
Interest Income
711.4M 495.9M 160.1M n/a
Pretax Income
4.78B 4.2B 4.86B 9.33B
Net Income
4.41B 3.95B 4.34B 8.08B
Selling & General & Admin
2.9B 2.54B 2.12B 1.82B
Research & Development
4.62B 3.99B 3.06B 2.62B
Other Expenses
53.4M -2.1M -89.9M -45.6M
Operating Expenses
7.58B 6.52B 5.08B 4.4B
Interest Expense
55.2M 73M 59.4M 57.3M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
10.03B 8.77B 6.79B 7.12B
Income Tax Expense
367.3M 245.7M 520.4M 1.25B
Shares Outstanding (Basic)
107.9M 106.7M 107.1M 105.7M
Shares Outstanding (Diluted)
115.1M 113.7M 113.5M 112.2M
EPS (Basic)
40.90 37.05 40.51 76.40
EPS (Diluted)
38.34 34.77 38.22 71.97
EBITDA
5.32B 4.69B 5.26B 9.67B
EBIT
4.84B 4.27B 4.92B 9.38B
Depreciation & Amortization
482.9M 421M 341.4M 286.2M